Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor
  - NAION I Privosegtor
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01 Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor Post-Ocular Surgery
  - NAION I Privosegtor Dry Eye Disease
Our Innovation
Investors and Media
- Column
- Column

Event Details

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

LSX Investival Showcase – IPO Bootcamp

Nov 7, 2023

Virtual

A case study presentation by Oculis’ CEO, Dr. Riad Sherif

Visionary Innovation

Our Company
About Us
Governance
Our Culture
Contact Us
Join Us
LinkedIn

Our Areas of Focus
Ophthalmology
Diabetic Macular Edema I OCS-01
Dry Eye Disease I Licaminlimab
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
NAION I Privosegtor

Our Innovation
Pipeline
Clinical Trials
Expanded Access Policy
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
In the News
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2026 Oculis All Rights Reserved

Terms of Use
Privacy Notice
Cookie Policy
Expanded Access Policy